Table 5.
Adjusteda Complication Rates and Healthcare Resource Utilization, 2015–2019
| Parameter | Patients receiving liposomal bupivacaine in the hospital, N (%) (N = 377) | Patients receiving liposomal bupivacaine in an ambulatory surgery center, N (%) (N = 129) | Odds ratio | P value |
|---|---|---|---|---|
| Complications | ||||
| Any complication | 41 (10.9) | 10 (7.8) | 0.53 (95% CI, 0.21–1.37) | .1926 |
| DVT or PE | 3 (0.8) | 1 (0.8) | 0.77 (95% CI, 0.04–14.38) | .8630 |
| Dislocation or fracture | 1 (0.3) | 0 (0) | NA | NA |
| Infection | 3 (0.8) | 1 (0.8) | 0.26 (95% CI, 0.01–6.42) | .4091 |
| Other | 38 (10.1) | 8 (6.2) | 0.54 (95% CI, 0.19–1.51) | .2390 |
| Healthcare resource utilization | ||||
| Emergency department visit without admission | 41 (10.9) | 4 (3.1) | 1.65 (95% CI, 0.49–5.54) | .4203 |
| Hospital admission (± emergency department visit) | 17 (4.5) | 3 (2.3) | 0.43 (95% CI, 0.09–2.15) | .3063 |
| Return to surgery in <8 wks | 4 (1.1) | 3 (2.3) | 0.10 (95% CI, 0.01–1.05) | .0552 |
| Return to long-term opioid use for pain in 8 wks | 9 (2.4) | 3 (2.3) | 0.90 (95% CI, 0.17–4.76) | .9025 |
a
Model covariates included age and sex.
CI indicates confidence interval; DVT, deep-vein thrombosis; NA, not applicable; PE, pulmonary embolism.